EUVIMEDEUVIMED entdecken
Crossref

Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription

Elise Dreano, Pierre Régis Burgel iD, Aurelie Hatton iD, Naim Bouazza, Benoit Chevalier, Julie Macey, Sylvie Leroy, Isabelle Durieu, Laurence Weiss, Dominique Grenet, Nathalie Stremler, Camille Ohlmann und 34 weitere

European Respiratory Journal · 2023-10 · 62 (4) · 2300110

DOI: 10.1183/13993003.00110-2023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Respiratory Journal, online erschienen am 11.09.2023. Verfasst von Elise Dreano und 45 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, CNRS, Institut Necker Enfants Malades, Paris, France. Hauptthemen laut MEDLINE: Cystic Fibrosis. Die Arbeit wurde bisher 100-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: Association Vaincre la Mucoviscidose.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Around 20% of people with cystic fibrosis (pwCF) do not have access to the triple combination elexacaftor/tezacaftor/ivacaftor (ETI) in Europe because they do not carry the F508del allele on the CF transmembrane conductance regulator ( CFTR ) gene. Considering that pwCF carrying rare variants may benefit from ETI, including variants already validated by the US Food and Drug Administration (FDA), a compassionate use programme was launched in France. PwCF were invited to undergo a nasal brushing to investigate whether the pharmacological rescue of CFTR activity by ETI in human nasal epithelial cell (HNEC) cultures was predictive of the clinical response.

Methods

CFTR activity correction was studied by short-circuit current in HNEC cultures at basal state (dimethyl sulfoxide (DMSO)) and after ETI incubation and expressed as percentage of normal (wild-type (WT)) CFTR activity after sequential addition of forskolin and Inh-172 (Δ I ETI/DMSO %WT).

Results

11 pwCF carried variants eligible for ETI according to the FDA label and 28 carried variants not listed by the FDA. ETI significantly increased CFTR activity of FDA-approved CFTR variants (I601F, G85E, S492F, M1101K, R347P, R74W;V201M;D1270N and H1085R). We point out ETI correction of non-FDA-approved variants, including N1303K, R334W, R1066C, Q552P and terminal splicing variants (4374+1G>A and 4096-3C>G). Δ I ETI/DMSO %WT was significantly correlated to change in percentage predicted forced expiratory volume in 1 s and sweat chloride concentration (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cystic FibrosisHumansCystic Fibrosis Transmembrane Conductance RegulatorDimethyl SulfoxideMutationPyrazolesPyridinesPyrrolidinesAminophenolsQuinolonesIndolesBenzodioxoles

Substanzen

Cystic Fibrosis Transmembrane Conductance RegulatorDimethyl SulfoxideelexacaftorPyrazolesPyridinesPyrrolidinesivacaftorAminophenolsQuinolonestezacaftor

Autor:innen und Institutionen

  • INSERM, CNRS, Institut Necker Enfants Malades, Paris, France.
  • Université Paris-Cité, Paris, France.
  • Respiratory Medicine and Cystic Fibrosis National Reference Center, Cochin Hospital, AP-HP, Paris, France.
  • INSERM U1016, Institut Cochin, Paris, France.
  • ERN-LUNG CF Network, Frankfurt, Germany.
  • Unité de Recherche Clinique, Hôpital Necker Enfants Malades, AP-HP, Paris, France.

ORCID-Profile: Pierre Régis Burgel, Aurelie Hatton, Anne Guillaumot, Adrien Tissot, Muriel Lebourgeois, Clémence Martin, Alexandre Hinzpeter, Emmanuelle Girodon, Isabelle Sermet-Gaudelus

Förderung

  • Association Vaincre la Mucoviscidose

Zitieren

APA

Dreano, E., Burgel, P. R., Hatton, A., Bouazza, N., Chevalier, B., Macey, J., Leroy, S., Durieu, I., Weiss, L., Grenet, D., Stremler, N., Ohlmann, C., Reix, P., Porzio, M., Roux Claude, P., Rémus, N., Douvry, B., Montcouquiol, S., Cosson, L., …, & French CF Reference Network study group (2023). Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription. European Respiratory Journal, 62(4), 2300110. https://doi.org/10.1183/13993003.00110-2023

Vancouver

Dreano E, Burgel PR, Hatton A, Bouazza N, Chevalier B, Macey J, et al. Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription. European Respiratory Journal. 2023;62(4):2300110. doi:10.1183/13993003.00110-2023

BibTeX
@article{Dreano2023,
  author = {Dreano, Elise and Burgel, Pierre Régis and Hatton, Aurelie and Bouazza, Naim and Chevalier, Benoit and Macey, Julie and Leroy, Sylvie and Durieu, Isabelle and Weiss, Laurence and Grenet, Dominique and Stremler, Nathalie and Ohlmann, Camille and Reix, Philippe and Porzio, Michele and Roux Claude, Pauline and Rémus, Natacha and Douvry, Benoit and Montcouquiol, Sylvie and Cosson, Laure and Mankikian, Julie and Languepin, Jeanne and Houdouin, Veronique and Le Clainche, Laurence and Guillaumot, Anne and Pouradier, Delphine and Tissot, Adrien and Priou, Pascaline and Mély, Laurent and Chedevergne, Frederique and Lebourgeois, Muriel and Lebihan, Jean and Martin, Clémence and Zavala, Flora and Da Silva, Jennifer and Lemonnier, Lydie and Kelly-Aubert, Mairead and Golec, Anita and Foucaud, Pierre and Marguet, Christophe and Edelman, Aleksander and Hinzpeter, Alexandre and de Carli, Paola and Girodon, Emmanuelle and Sermet-Gaudelus, Isabelle and Pranke, Iwona and French CF Reference Network study group, French CF Reference Network study group},
  title = {Theratyping cystic fibrosis patients to guide elexacaftor/tezacaftor/ivacaftor out-of-label prescription},
  journal = {European Respiratory Journal},
  year = {2023},
  volume = {62},
  number = {4},
  pages = {2300110},
  doi = {10.1183/13993003.00110-2023}
}
Kostenlos starten →